A new study finds that baseline testing for HPV can better predict long-term negative cervical cancer outcomes compared to a Pap smear.
Results from a trial of a new therapeutic vaccine for renal cell carcinoma demonstrate that those patients with a measurable immune response to the vaccine have a prolonged overall survival.
A new study suggests suppression of breast cancer metastasis relies on an antitumor immune response. Researchers found that administering interferon can reduce bone metastases and increase the survival time of a metastatic breast cancer mouse model.
Last week the US Food and Drug Administration approved carfilzomib (Kyprolis) to treat patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib (Velcade) and an immunomodulatory therapy.
A new target of melanoma tumors has been identified that may be promising as part of a novel combination therapy for melanoma. In a study published in Nature Medicine, researchers have identified that more than half of melanoma cases, both early and late-stage, may have higher levels of MDM4, a p53-interacting protein.
The FDA approved the mTOR inhibitor everolimus (Afinitor) last week for use in postmenopausal women with HER2-negative, hormone-receptor-positive advanced breast cancer patients.
Three-year results from the ENESTnd trial show continued superiority of nilotinib over imatinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase, according to a new paper published online ahead of print in Leukemia in June.
Nilotinib offers good results for patients with Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase who are resistant or intolerant of imatinib, according to 48-month follow-up results of a phase II study.
The results of the 12-year PIVOT trial shows men with early-stage prostate cancer who had a radical prostatectomy did no better than those actively monitored without surgery.
The FDA has approved a new strategy to evaluate the risk and safety of both extended-release and long-acting opioid analgesic, called a Risk Evaluation and Mitigation Strategy (REMS). The drug class are synthetic versions of opium, that have had a long history of regulated control to mitigate their abuse and illegal distribution.